Ra223
Phase 3Small molecule
Ra223 is one of 31 small molecule programs targeting Phase II. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
33 competitors in Phase II
#DrugCompanyPhaseTrials
1Xtandi
AstellasPhase 3
Rituxan
RochePhase 2
Lynparza
AstraZenecaPhase 2
Polivy
RochePhase 2
Herceptin
RochePhase 2
Imfinzi
AstraZenecaPhase 2
Adriamycin
PfizerPhase 2
LUNSUMIO
RochePhase 2
Tyrosine Kinase Inhibitor
PfizerPhase 3
SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Phase II1 trial
Phase III Radium 223 mCRPC-PEACE III
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT02194842·446 enrolled
Metastatic Hormone-Sensitive Prostate Cance1 trial
Quantitative Unified Assessment of Novel Triplet Therapy and Unconventional Maintenance With Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer: A Phase II Pilot Trial
Not yet recruiting·AAlianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD·Phase 2·NCT07717099·50 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ra223. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details